Cargando…

A family history of breast cancer will not predict female early onset breast cancer in a population-based setting

BACKGROUND: An increased risk of breast cancer for relatives of breast cancer patients has been demonstrated in many studies, and having a relative diagnosed with breast cancer at an early age is an indication for breast cancer screening. This indication has been derived from estimates based on data...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Bock, Geertruida H, Jacobi, Catharina E, Seynaeve, Caroline, Krol-Warmerdam, Elly MM, Blom, Jannet, van Asperen, Christi J, Cornelisse, Cees J, Klijn, Jan GM, Devilee, Peter, Tollenaar, Rob AEM, Brekelmans, Cecile TM, van Houwelingen, Johannes C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515321/ https://www.ncbi.nlm.nih.gov/pubmed/18651949 http://dx.doi.org/10.1186/1471-2407-8-203

Ejemplares similares

Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases
por: Huijts, Petra EA, et al.
Publicado: (2007)

Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
por: Verhoog, L C, et al.
Publicado: (2000)

Comment on Screening by MRI Mentioned in the Reviews by Narod and Møller
por: Kriege, Mieke, et al.
Publicado: (2004)

Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy
por: Tan, Murly BM, et al.
Publicado: (2009)

Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2
por: Oldenburg, RA, et al.
Publicado: (2005)

Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10
por: Huijts, Petra EA, et al.
Publicado: (2011)

Author Reply: Decision-Making Management of Women with a High Risk of Developing Breast and Ovarian Cancer
por: Heemskerk-Gerritsen, Bernadette, et al.
Publicado: (2008)

Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients
por: Bock, G H de, et al.
Publicado: (2001)

Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients
por: Papelard, H, et al.
Publicado: (2000)

Breast Cancer Screening in High-Risk Women
por: Brekelmans, C. T. M., et al.
Publicado: (1999)

MUTYH gene variants and breast cancer in a Dutch case–control study
por: Out, Astrid A., et al.
Publicado: (2012)

Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families
por: Peelen, T, et al.
Publicado: (2000)

Remarks on the BOADICEA model of genetic susceptibility to breast and ovarian cancer
por: van Asperen, C J, et al.
Publicado: (2005)

Discovering genetic profiles by array-CGH in familial breast tumors
por: Nederlof, PM, et al.
Publicado: (2005)

Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial
por: Saadatmand, Sepideh, et al.
Publicado: (2012)

Effectiveness and cost-effectiveness of meaning-centered group psychotherapy in cancer survivors: protocol of a randomized controlled trial
por: van der Spek, Nadia, et al.
Publicado: (2014)

Effectiveness and cost-effectiveness of meaning-centered group psychotherapy in cancer survivors: protocol of a randomized controlled trial
por: van der Spek, Nadia, et al.
Publicado: (2018)

Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling
por: Hilbers, Florentine S., et al.
Publicado: (2013)

Clustering of known low and moderate risk alleles rather than a novel recessive high‐risk gene in non‐BRCA1/2 sib trios affected with breast cancer
por: Hilbers, Florentine S., et al.
Publicado: (2020)

Loss of heterozygosity on chromosome arm 16q in breast cancer: clinical, molecular and statistical approaches
por: Cleton-Jansen, A-M, et al.
Publicado: (2000)

Genetic clinicians' confidence in BOADICEA comprehensive breast cancer risk estimates and counselees' psychosocial outcomes: A prospective study
por: Brédart, Anne, et al.
Publicado: (2022)

General Practitioners and Breast Surgeons in France, Germany, Netherlands and the UK show variable breast cancer risk communication profiles
por: Julian-Reynier, Claire, et al.
Publicado: (2015)

Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2007)

Genetic counselling and the intention to undergo prophylactic mastectomy: effects of a breast cancer risk assessment
por: van Dijk, S, et al.
Publicado: (2003)

Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies
por: Gonzalez-Neira, Anna, et al.
Publicado: (2007)

Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.
por: Cleton-Jansen, A. M., et al.
Publicado: (1995)

Expression analysis of candidate breast tumour suppressor genes on chromosome 16q
por: van Wezel, Tom, et al.
Publicado: (2005)

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers
por: Kriege, Mieke, et al.
Publicado: (2015)

Design of the BRISC study: a multicentre controlled clinical trial to optimize the communication of breast cancer risks in genetic counselling
por: Ockhuysen-Vermey, Caroline F, et al.
Publicado: (2008)

Do Preferred Risk Formats Lead to Better Understanding? A Multicenter Controlled Trial on Communicating Familial Breast Cancer Risks Using Different Risk Formats
por: Henneman, Lidewij, et al.
Publicado: (2020)

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
por: Kriege, M, et al.
Publicado: (2014)

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
por: van Sprundel, T C, et al.
Publicado: (2005)

Tumor stroma as contributing factor in the lymph node metastases process?
por: Mesker, Wilma E., et al.
Publicado: (2019)

Correction: Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
por: Mesman, Romy L. S., et al.
Publicado: (2020)

Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
por: Mesman, Romy L. S., et al.
Publicado: (2020)

Low-risk susceptibility alleles in 40 human breast cancer cell lines
por: Riaz, Muhammad, et al.
Publicado: (2009)

Impact of screening for breast cancer in high-risk women on health-related quality of life
por: Rijnsburger, A J, et al.
Publicado: (2004)

Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study
por: Wevers, M. R., et al.
Publicado: (2015)

Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis
por: Hensen, Erik F, et al.
Publicado: (2009)

The functional impact of variants of uncertain significance in BRCA2
por: Mesman, Romy L. S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6510go5sobh8obq305kcia3jcm